

Ref: MHL/Sec&Legal/2020-21/152

Date: November 11, 2020

To,  
**Head, Listing Compliance Department**  
**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai - 400 001.

**Scrip Code: 542650**

**Head Listing Compliance Department**  
**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051.

**Scrip Symbol: METROPOLIS**

**Sub: Intimation of Investor presentation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015**

Dear Sir/Madam,

With reference to the captioned subject, we herein enclose a copy of the Investor Presentation for the quarter and half year ended September 30, 2020.

You are requested to take the above information on record.

Thanking You,

Yours Faithfully,  
For **Metropolis Healthcare Limited**



Poonam Tanwani  
**Company Secretary and Compliance Officer**  
Membership No.: ACS 19182

Encl. a/a

**BLOOD TESTS • DIAGNOSTICS • WELLNESS**

**METROPOLIS**  
The Pathology Specialist

**Metropolis Healthcare Limited**


Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.  
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [support@metropolisindia.com](mailto:support@metropolisindia.com)

Website: [www.metropolisindia.com](http://www.metropolisindia.com)

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

# METROPOLIS

The Pathology Specialist



Reaching Out **RESPONSIBLY**  
Investor Presentation - November 2020

*This presentation and the accompanying slides (the “**Presentation**”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.*


*This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.*

*Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.*






“ Metropolis is a Strong Consumer  
Focused and Trusted Pathology Brand  
in the Indian Diagnostics space ...




”  
Quality Focus  
Large test Menu  
Customer Centricity Approach  
Technical & Scientific Team  
Pan India Presence

# Non-Covid revenue continues to gain traction..


## Non-Covid Revenues



## Covid Revenues



## Total Revenues




- ✓ With Increased level of normalized operations, *we have seen increased revenue on month-on-month basis*
- ✓ As we witnessed increased unlock situation across the country, *our non-covid revenue witnessed faster traction*
- ✓ In September 2020, we achieved marginal growth in non-covid revenues over September 2019
- ✓ *Our focus to scale up Non-Covid tests in Q2 has paid off* as we continue to provide one the best facilities in terms of safety coupled with Home Visit services
- ✓ *B2G revenue* have also started to contribute meaningfully *aiding recovery* in non-covid revenue
- ✓ As number of Covid cases moderated complemented by increased public awareness for Home Quarantine along with reduced pricing, *Covid revenue witnessed a dip in September as compared to August*

# Healthy revenue growth... led to operating leverage benefits


Month-wise Revenue (In Crs.)

Month-wise EBIDTA (In Crs.)


July




July




August




August



September




September



- ✓ As Covid-19 lockdown started easing and travel restrictions on people were lifted, the business continued to pick up much faster than anticipated as people have adapted to the new normal
- ✓ Company has not only recovered from the pandemic but have also grown as compared to last year same period. **Revenue grew by 13% in July, 30% in August and 45% in September on YoY basis**
- ✓ With the help of increasing revenue and cost optimization efforts by the company, operating leverage benefits played out leading to **record operating margins**

# Operating Leverage benefits played out in Q2FY21




- ✓ Cost optimization efforts, superior product mix along with Automation and Digitization **led to record EBIDTA margins in Q2FY21**
- ✓ For Q3FY21, we expect the **Non-Covid revenue to achieve normalcy** while Covid revenue performance is unpredictable and is likely to be dependent on external factors




# Steady Focus on Balance Sheet continues


Debtors Days\*#



Working Capital Days\*




OCF to EBITDA




Cash and Cash Equivalents

Rs. In Crs



- ✓ *We have continued to focus on collection efficiency* and improved our Debtor days & Overall Working Capital days
- ✓ Metropolis is a Zero-Debt company with growing cash & cash equivalents year on year basis. *Cash & Cash Equivalents as on Sep 2020 stood at Rs. 325 crs*
- ✓ Healthy OCF / EBITDA at *89% in H1FY21 as compared to 93% in FY20*
- ✓ Our *OCF to EBITDA ratio remains healthy and with no large Capex requirements*, Free Cash flows of the company will further strengthen Balance Sheet to support growth

# Q2 & H1 FY21 Consolidated Financial Performance



## Revenue

- ✓ H1FY21 Revenue increased YoY in spite of tepid Q1FY21
- ✓ Q2FY21 Revenue increased by 29% YoY on the back of strong Non-Covid Revenue
- ✓ Non-Covid Revenue continued to increase MoM and expected to continue the growth momentum

## EBIDTA


- ✓ EBIDTA (Before CSR & ESOP) for Q2FY21 stood at Rs. 95.0 Crs, up by 50.8% YoY. Margins for Q2FY21 stood at 32.9%, expanded by 470 bps YoY
- ✓ Increased revenue and several cost optimization efforts undertaken by the company have led to this margin improvement

## PAT


- ✓ Q2FY21 PAT stood at Rs. 60.5 crs, up by 40% YoY
- ✓ Q2FY21 PAT Margin stood at 21.0%, expanded by 170 bps YoY

# Operating Performance


No. of Patient Visits (In Mn.)




Revenue Per Patient (In Rs.)



No. of Tests (In Mn.)




Revenue per Test (In Rs.)




- ✓ Revenue per Patient & Revenue per Test has increased on account of high value Covid-19 test
- ✓ Increased volumes of the specialized non-covid tests *led to growth in Revenue per patient and Revenue per test*
- ✓ On a like to like basis (Non-Covid) *Revenue per Patient & Revenue per Test stands at Rs. 926 & Rs. 444 respectively*
- ✓ As lockdown continues to ease, we expect revenue share from Non-Covid tests to continue to increase and improve the profitability

Laboratory Network



Service Network



## Network Strategy Highlights

### Young Individuals Patients Network

- ✓ The average retail centre matures in five years. As the network matures, it is expected to contribute to short and mid term future growth. There is an opportunity for our franchisee network which is opened in last four years to grow as per matured centres
- ✓ We are seeing healthy growth in average revenue per centre in the third party centre segment.

### Asset Light Network


- ✓ 90.5% of the centre network and 16.1% lab network is asset light
- ✓ Major addition in the labs in FY19 and FY20 is through lab on lease model which is asset light with no capital requirement

### Rationalization of Service Network


- ✓ Service Network reduced by ~10% between Apr to Sep-20 to optimise the service network
- ✓ Rationalization exercise is largely completed and will lead to better productivity and efficiency as well as improvement in Management Bandwidth
- ✓ Focus to be on scaling up and nurturing existing service network to enhance efficiency of the centre and its profitability
- ✓ Revenue contribution from closure of the Service network – Less than 0.5% of total revenue

# Share of B2C Business in Focus Cities (Non-Covid) at 60% in Q2FY21

B2C Contribution in Focus Cities for Q2FY21 (excl. Covid-19 Revenues)



B2C Contribution in Focus Cities (excl. Covid-19 Revenues) (Rs. in Crs)




- ✓ Excluding Covid-19 revenues, our B2C contribution continues to increase
- ✓ Our aspirations is to achieve 65% B2C contribution in focused cities in coming years remains intact, driven by;
  - Aggressive **network expansion** to go closer to the patient
  - Integrated **Brand building campaigns** to establish Metropolis as a trusted brand in the mind of consumer and the doctor
  - **Building awareness** amongst doctors for quality and service differentiators of Metropolis vs the unorganized sector.
  - Obsessively monitoring customer experience and generating a **Net Promoters Score (NPS)**




# Market Dynamics – a long runway of growth

Revenue Mix between Focus, Seeding & Others Cities



Revenue Mix between Geographies



## ***Diversified Revenue Mix***


- ✓ Increased Covid testing in urban cities especially western India has led to increased contribution from focus cities in Q2FY21
- ✓ Opportunity to increase market share in focus cities is very high especially through the B2C route and a combination of our young network along with improving revenue per center; this will create a long runway for growth

# High Value Specialized Tests is increasing...


Q2FY20

Q2FY21

Volume Mix (Including Covid-19)




Volume Mix (Excluding Covid-19)





Q2FY20

Q2FY21

Value Mix (Including Covid-19)



Value Mix (Excluding Covid-19)



## Diversified Volume & Value Mix

- ✓ Including Covid-19 Tests which are part of specialized tests the volume & value mix for specialized tests has seen an improvement
- ✓ With increasing unlock in Q2FY21, we have witnessed an increased flow in specialized tests from increase in elective surgeries on a Q-o-Q basis
- ✓ Our capabilities on testing on back of large test menu ensures faster penetration of metropolis brand in geographies thus creating a strong and trusted consumer brand

## Healthy and Motivated Employees is a priority for Metropolis

- ✓ **Metropolis announces increments** to its country wide employees for their selfless services during the ongoing pandemic
- ✓ **MD Shaurya Award for the frontline staff** for standing strong with the core purpose of MHL. Ameera Shah, MD, Metropolis Healthcare has rewarded the employees with a bonus from her own personal account in appreciation of their work and commitment during the ongoing pandemic
- ✓ **Rewarding Performance** - ESOPs for Senior Management
- ✓ **The company has ensured regular testing** and provision of medical assistance for all its employees and their immediate family member
- ✓ **An employee welfare** fund has been constituted as well as a re-look at all the insurance schemes to ensure the staff is covered according to the pandemic situation





## Strengthening Existing IT systems


- ✓ **Inhouse support for Digital Platform** - enabled reduction of resolution TAT and reduction on daily ticket counts
- ✓ **Health Data Analytics** – Delivered dashboards of Patient Summary, Visit Summary, Department & Test Summary Chronic Patient Analysis
- ✓ **Secure MHL** – Continuous monitoring of our application, database & storage servers

## Information Technology – Near Term Targets


- ✓ **Consolidation of cloud infrastructure & robust end user support**
- ✓ **Finalizing partners for long term digital transformation in B2B/B2C**
- ✓ **Establish Information Security & Data Privacy Framework based on ISO27001 & Draft India Personal Data Protection Bill**

**Metropolis Health Care Limited is leveraging Technology to** continually upgrade and address evolving business needs thereby achieving higher efficiency and productivity levels

# Ramping up Home Testing offerings



Home Visits as a % of B2C business  
(Excluding Covid-19)




Increasing Coverage

**Target to increase Home Visit footprint from currently 9 locations to over 65 locations by Dec-2020**

**Home visit testing** is scaling on month on month basis and enjoys a better margin profile



# Enhancing Customer Experience... Digitally



Increased communication efforts through **Rigorous Campaigns** to assure customers on safety and hygiene of Metropolis centers and Home testing services


Fully **Integrated Website and APP** for Online booking, multiple payment modes, digital reports, report storage as well as enabling doctor engagement through Digital medium

Introduced **'Symptom checker'** on website and APP as part of our initiative to educate customers

Extensive communication efforts through **Social Media Platforms** to reach out to our Target audience to make the aware of our Presence for testing

Through Our Digital engagement efforts, we have substantially increased our Brand equity, in the mind of Customers, as a **Trusted and Reliable Healthcare Service Provider**

*All customer communications and engagement digitally with customers through **using best in class technology***



***Our Focus is to become a complete end to end digital service provider** not only for our customers, but also for our every stakeholder including doctors, vendors and digital partners*

## Initiatives taken

### Metropolis Website Revamp


- ✓ User friendly and responsive website
- ✓ User account, Download report
- ✓ E-comm website
- ✓ SEO friendly site

### Hyper local activity:


- ✓ Optimized 640 stores

### Hyper local activity:

- ✓ Rightly optimized digital campaigns in focused markets to increase digital presence
- ✓ Own database engagement campaigns



## Business Impact



*Digital strategy is playing important role & will be the key driver for*



*Brand Creation*



*Lead Generation*



*Customer Experience*

# Consolidated Profit & Loss Statement

Particulars (Rs. Crs.)	Q2FY21	Q2FY20	Y-o-Y	H1FY21	H1FY20	Y-o-Y
<b>Revenue from Operations</b>	<b>288.6</b>	<b>223.3</b>	<b>29.2%</b>	<b>431.2</b>	<b>426.6</b>	<b>1.1%</b>
Cost of Raw Material Consumed	74.4	52.7		112.6	100.9	
Laboratory Testing Charges	0.9	1.5		2.9	3.1	
Employee Expenses	46.2	49.6		91.6	96.6	
Other Expenses	71.9	56.5		116.2	107.4	
<b>EBIDTA (before CSR and ESOP)</b>	<b>95.0</b>	<b>63.0</b>	<b>50.8%</b>	<b>107.8</b>	<b>118.6</b>	<b>-9.1%</b>
<b>EBIDTA (before CSR and ESOP) Margin</b>	<b>32.9%</b>	<b>28.2%</b>		<b>25.0%</b>	<b>27.8%</b>	
CSR	0.2	0.2		0.3	0.5	
ESOP	2.4	0.2		3.0	0.4	
<b>Reported EBIDTA</b>	<b>92.5</b>	<b>62.6</b>	<b>47.7%</b>	<b>104.6</b>	<b>117.7</b>	<b>-11.1%</b>
<b>Reported EBIDTA (%)</b>	<b>32.0%</b>	<b>28.0%</b>		<b>24.3%</b>	<b>27.6%</b>	
Other Income net of Finance Cost	-0.1	0.1		1.2	-0.1	
Depreciation	11.0	9.3		20.9	17.7	
Exceptional Items	0.0	0.0		0.0	6.9	
Share of loss for equity accounted investee (net of tax)	0.0	-0.2		0.0	-0.5	
<b>Profit Before Tax</b>	<b>81.4</b>	<b>53.2</b>	<b>53.0%</b>	<b>84.9</b>	<b>92.5</b>	<b>-8.2%</b>
<b>Margin (%)</b>	<b>28.2%</b>	<b>23.8%</b>		<b>19.7%</b>	<b>21.7%</b>	
Tax	20.9	10.1		21.5	22.5	
<b>Reported Profit After Tax</b>	<b>60.5</b>	<b>43.1</b>	<b>40.3%</b>	<b>63.4</b>	<b>70.0</b>	<b>-9.4%</b>
<b>Reported Profit After Tax (%)</b>	<b>21.0%</b>	<b>19.3%</b>		<b>14.7%</b>	<b>16.4%</b>	

# Consolidated Balance Sheet

Assets (Rs. Crs.)	Sep-20	Mar-20
<b>Non-current assets</b>	<b>349.9</b>	<b>355.2</b>
Property, Plant and Equipment	118.7	121.2
ROU Assets	52.5	59.7
Goodwill	90.4	90.3
Other intangible assets	27.0	25.2
Intangible assets under development	2.0	3.0
ROU Assets		
<b>Financial Assets</b>		
(i) Investments	1.8	1.8
(ii) Loans	6.1	5.5
(iii) Other Financial Assets	3.9	12.4
Deferred Tax Assets (Net)	18.4	13.9
Other non-current assets	6.6	6.4
Non-current tax assets (net)	22.6	15.9
<b>Current assets</b>	<b>504.1</b>	<b>397.1</b>
Inventories	30.9	24.4
<b>Financial Assets</b>		
(i) Investments	14.1	12.6
(ii) Trade receivables	125.2	128.2
(iii) Cash and cash equivalents	230.4	107.2
(iv) Bank balances other than (iii)	81.0	103.3
(v) Loans	7.9	11.2
(vi) Other Financial Assets	1.3	2.2
Other Current Assets	13.4	8.0
<b>TOTAL - ASSETS</b>	<b>854.1</b>	<b>752.2</b>

Equity & Liabilities (Rs. Crs.)	Sep-20	Mar-20
<b>Equity</b>	<b>613.9</b>	<b>525.2</b>
Equity Share capital	10.2	10.1
Other equity	601.8	513.4
Non Controlling Interest	1.9	1.7
<b>Non-current liabilities</b>	<b>50.2</b>	<b>57.6</b>
<b>Financial Liabilities</b>		
(i) Borrowings	-	-
(ii) Lease Liabilities	40.4	45.8
(ii) Other Non-Current Liabilities	1.4	4.7
Provisions	6.5	5.4
Deferred tax liabilities (Net)	2.0	1.7
<b>Current liabilities</b>	<b>190.1</b>	<b>169.5</b>
<b>Financial Liabilities</b>		
(i) Borrowings	-	-
(ii) Lease Liabilities	20.6	20.9
(iii) Trade Payables	108.9	85.0
(iv) Other Current Financial Liabilities	36.3	34.4
Other Current Liabilities	12.6	18.8
Provisions	7.4	6.6
Current tax liabilities (Net)	4.5	3.7
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>854.1</b>	<b>752.2</b>



Cash Flow Statement (Rs. Crs)	H1FY21	H1FY20
Profit Before Tax	84.9	92.5
Adjustments for Depreciation and other items	40.6	32.2
Operating profit before working capital changes	125.5	124.8
Changes in working capital	-0.06	11.5
<b>Cash generated from operations</b>	<b>125.4</b>	<b>136.2</b>
Direct taxes paid (net of refund)	-31.9	-33.6
<b>Net Cash from Operating Activities (A)</b>	<b>93.5</b>	<b>102.6</b>
<b>Net Cash from Investing Activities (B)</b>	<b>17.9</b>	<b>-64.6</b>
<b>Net Cash from Financing Activities (C)</b>	<b>10.1</b>	<b>-26.4</b>
<b>Net Change in cash and cash equivalents</b>	<b>121.5</b>	<b>11.6</b>

## 01 Strong Brands to benefit

Unorganised standalone labs are facing challenges in terms of operations due to stringent quality norms and lack of customer faith in their operations

## 03 Covid-19 capable labs

Covid-19 will become a new normal test in times to come;; consumers will view diagnostics chains as Covid-19 capable labs & Non-Covid-19 labs

## 05 Faster Consolidation and regulatory adoption

We expect faster consolidation in the industry & positive changes in the regulatory framework



## 02 Customer to focus on Quality rather than pricing

Expecting the Indian consumer to be more quality conscious with respect to healthcare thereby benefiting the larger organized diagnostics chains

## 04 Consumer Connect

Diagnostics chain with lean Balance Sheet, Strong Consumer Connect & High focus on Quality will gain market share



# Overview

# We are Metropolis: The Pathology Specialist

## Vision

To be a respected healthcare brand trusted by clinicians, patients and stakeholders. Positively impact lives of patients in their most anxious times and turn their anxiety in to assurance.

## Mission

Helping people stay healthy, by accurately revealing their inner health



## INTEGRITY

is in our  
**VEINS**



## EMPATHY

is in our  
**BLOOD**



## ACCURACY

is in our  
**DNA**



**35+ Years of  
Credible Operations**



**Leading Diagnostic  
player in India**



**4,000+ Tests &  
Profiles**




**Presence in 19  
States & 210 Cities**



**20 Mn Tests & 10 Mn  
Patient Visit in FY20**


# Journey to Leadership Position







## Leadership Position Across Industry



## METROPOLIS Focus Area



# Key Drivers for Growth

01

Industry Growth

02

Value Chain

03

Business Model

04

Service Network

05

Expansion Plan

06

Quality

07


People

08


Digital Transformation

# 1a. Diagnostic Industry Poised to grow...


**Size of Indian Healthcare Industry**




**Size of Indian Diagnostics Market**




**Indian Diagnostics Industry Breakup**





**Diagnostic Industry highly fragmented**



**Diagnostic Chains Presence**



## 1b. Top players to continue to acquire market share of standalone centers



**Metropolis is amongst the Front runners for Consolidation**

Established track record of successful acquisition and integration in India and overseas

**Less than 20% of the Diagnostics Sector in India is organized with limited Pan India presence and focus on Quality Parameters in Testing**

# 2. Presence in key pockets of Value Chain

## Diagnostic Industry - Fragmented

Highly Fragmented Market  
Low Quality Standard



**Technician  
Run Lab**

Low on Technical Qualifications & Accreditations (99.9% labs remain un-accredited)



**Pathologist  
Run Lab**

Non-Compliant: Governance, Legal, Medical



**Hospital  
Run Lab**

No Technology Up-gradation  
No Customer Service

Un-sustainable and un-scalable business model



**Leading  
Diagnostics Chains  
at an advantage**

High Quality Standards with Large Test Menu

Customer Convenience

Highly Compliant w.r.t Governance, Legal & Medical regulations

Sustainable and Scalable Business Model

Years of experience, brand value and delivering value to all stakeholders

### Routine Test

Majority Diagnostic Players  
+  
Moderate Competition  
+  
High Margins in %

### Semi-Specialized Test

Few Focused Players  
+  
Intense Competition and Highly Commoditized  
+  
Packages and Test Menu is Key

### Specialized Test

Few Players as market demands high accuracy and Quality Parameters  
+  
Low Competition  
+  
High absolute margin but low volumes

## Metropolis Focus


Presence across Value Chain as we are a National Player

Focus on High Value added Specialized Test

Resulting High Quality Earnings and Profitability

Metropolis - Test Mix	FY19		FY20	
	Volumes Mix	Value Mix	Volumes Mix	Value Mix
Routine	35%	17%	39%	18%
Semi Specialized	41%	37%	38%	37%
<b>Specialized</b>	<b>16%</b>	<b>41%</b>	<b>15%</b>	<b>37%</b>
Wellness	8%	5%	8%	8%

### 3. Hub & Spoke Model to scale efficiently



# 4. Patient Centric Network

More than **~4,000**  
Test's & Profiles

Present in **19 States**  
& **210 cities**

**Global and  
National  
Quality  
Accreditations**

**Over 10,000** Patient  
Touch Points

**35+ Years**  
of Credible Operations



**1**

Global Reference Lab in  
Mumbai

Routine + Semi-Specialized  
+ Specialized

**~4,000+ Test**  
**~40,000 Sq. Ft**



**13**

Regional Labs

**10** in India; **3** Outside India

Routine + Semi-Specialized  
+ Few Specialized

**~500+ Test**  
**~8,000 – 10,000 Sq. Ft**



**47**

Express Labs; 5 outside India

**64**

Satellite Labs; 1 outside India

Routine  
Tests

**~25-150 Test**  
**~1,000-2,500 Sq. Ft**



**2,447** Collection Centers

**249**

Owned PSC's

**1,721**

3rd Party PSC's

**477**

ARC's

Collection  
Centers

**~200 – 1,000 Sq. Ft**


## Why Metropolis ?

- ✓ Conclusive Diagnosis with Large test Menu backed by Highest standards of Quality
- ✓ Customer Focused Services with convenience and test accuracy at the core of service standard
- ✓ Large Un-Paralleled Service network with Pan India Presence
- ✓ Consistency in operations in every single visit from seamless blood collection, hygienic collection setup to timely report delivery



## 5. Asset Lite Expansion Plan


### Asset Light Model



### Network Expansion Strategy

- ✓ Focus on **Asset Light Model** to achieve Geographic Expansion with High Scalability
- ✓ The **A-PSC and D-APSC** Model allows us to grow our revenues by providing management and branding support while continuing to focus on increased penetration in our PSCs
- ✓ Better **Leverage of our Existing Infrastructure** by establishing a wider geographic reach which will enable customer base expansion and improvement in profitability matrix
- ✓ Establish strategic partnerships with **3rd Party Patient Service Centers** in India, Africa and Middle East to boost our Geographic reach

# 6a. Quality in Core




## Quality protocols following global standards

99.9% of industry labs remain un-accredited with lack of minimum standards in the industry



## Best medical talent trained in the Metropolis way

Talent in the industry remains un-trained with no benchmarks of minimum standards



## Quality of materials used are USFDA or CE marked

Commonly used materials by industry labs are low quality



## Patient experience score as per NPS is at 91%

Patient experience in industry labs is of poor infrastructure, lack of hygiene and safety and un-professional service



## Ethical philosophy of putting patient first

Common practice in industry is to take shortcuts to enhance profit

**Trust & Sustainability of our Brand is “CRITICAL TO OUR SUCCESS”**

# 6b. Globally Compliant Quality Standards

## “Global Lab Accreditations”



- ✓ Mumbai Lab is CAP accredited since 2005 \*(College of American Pathologists, global gold standard in laboratory accreditations)
- ✓ NABL Accreditation follows ISO-15189 Standard and is recognized by ILAC & APLAC
- ✓ GRL and 11 RRLs have NABL accreditation.
- ✓ More than 75% reports are generated by accredited labs. Many of our doctor’s are assessors, lead assessors for NABL.
- ✓ Some senior doctors are committee members of NABL, WHO, Government & NGO committees.




## No. of Audits Conducted by PAC Team

FY	17-18	18-19	H1 20	FY 20
	665	1,312	597	1,057


- ✓ PAC Team: Special Pre Analytical Care Team constituted as part of the Quality Assurance Team
- ✓ This team conducts thorough internal audits as per NABL Checklist to ensure compliance for our collection centres and facilities

## NPS Score – PSC & Home Service




- ✓ Net Promoter Score (NPS for Owned & Home Service) is a scoring giving weightage to all those consumers who would recommend Metropolis after their experience minus any detractors who are unsatisfied with Metropolis Services.


## GRL CAP Proficiency Testing Score



## 7. People are our greatest asset



- ✓ New HR Management System for automated processes improving productivity and ensuring availability of employee data on demand
- ✓ System for nurturing second in line high performers
- ✓ Young, energetic and motivated team. Over 60% of workforce are millennial
- ✓ Hungry and experienced management team aligned to vision of the company




- ✓ Strong culture equal opportunity workplace
- ✓ Female : Male Ratio = 41:59
- ✓ 4,500 + Highly skilled and motivated Member base



- ✓ Full Fledged Learning Management System that is used for daily training across the Company.
- ✓ Strong scientific team led by expert MD Doctors and pathologists
- ✓ 216 - Doctors
- ✓ 2,626 – Scientific & Technical Team

# 8. Leveraging IT for Competitive Advantage



## Improving Business revenue generation capabilities

- ✓ **IBM Watson Campaign** Automation will help improve in additional leads and tracking
- ✓ Lead Management system will help **improve lead conversion rate**
- ✓ Data Analytics model on customer data will **improve Cross-Sell and Upsell**

## Cost Saving & Optimization

- ✓ Launching a Pricing Engine for better Revenue Assurance
- ✓ **Payment Platform** improving controls in Cash Management Process
- ✓ **Network Bandwidth Optimization (SD-WAN)**


## Improved Operational Efficiency

- ✓ **Zero Data Loss;** 100% data replication in remote location
- ✓ Implementation of Sample tracking process to **Improve Visibility of Customers & Turn Around Time (TAT) of reports.**
- ✓ **Automating HR processes through HRMS** for better tracking and possible productivity.
- ✓ Introduction of Learning Management System to training and development goals.
- ✓ **Automated Quality System** to track quality standards across the group

## Improve Customer Experience

- ✓ **Mobility Applications** for consumer's ease of access
- ✓ **Service CRM implementation** will help improve NPS
- ✓ **Feedback Management** will increase percentage of patient providing instant feedback and rating

## 8a. Digital Transformation to improve efficiency



Our information technology system allows us to fully Integrate and Automate processes ranging from **Registration, Bar-Coding and Billing of specimens to Analysis and Reporting of Test Results**



# Mobile App Launched in Q3FY20 with features enabling ease of access

## Expert TruHealth Risk Assessment TruHRA



Customized Check-ups

Booking Appointments

See, Share & Store Reports

Fitness Tracker

Inner Health Tracking Parameters


Medication Tracker

Doctor's, Hospital's & Metropolis nearby


Chat with Experts

Notification Center


Google of Test & Ailments – Health Hub








## App Review snapshots




**Nikki shehzaadii**  
★★★★★ 20 December 2019

Had a good experience of this app it is easy to book a home visit and track the report easily and also help to guide the center near me m happy with this app very usefull which also save time. 😊




**Ankush Chavan**  
★★★★★ 24 December 2019

Nice app. Take care about my health. Providing my health reports also and much more about health. Am happy use this app.thank you so much provide great app.



**Minal R**  
★★★★★ 20 December 2019

Very useful all-in-one health app. Many useful features for booking appointments, getting health score etc. A must have app



**Rehana Khan**  
★★★★★ 20 December 2019

Excellent app very helpful and useful....can find the details sitting anywhere and book visit as per our requirement on fingertips.....helpful and friendly app

Our Pilot Launch is successful with Positive reviews & Rating along with increased traction in Home booking

We are live from Q2 Onwards & expected to gain transaction in Q3 & Q4




**01**

**Increase Services**



**02**

**Increase Scale**



01

## Easy to Interpret Test Report

We offer our patients a Detailed Test Report which covers Result Trend Analysis and Patient Specific Interpretations and comments by our Doctors for certain tests and conditions

02

## Sample Collection from Doorstep

We have increased scope of our Home Collection service to ~200 cities in India

03

## Conclusive Diagnosis


We also have a policy of ensuring Conclusive Diagnosis to our patients, even if it involves incurring additional costs for us, by way of Re-Checks and Reflex testing on alternate technology

04

## Digital Access

We have developed a Mobile Application

- ✓ For scheduling house calls
- ✓ Accessing Test reports
- ✓ Receiving Test Reminders
- ✓ Online requests for Billing Information



## Increase B2C sales mix

### Deeper Network Penetration



Deeper centre penetration in Focused Cities on back of strong brand recognition to drive Individual patients to Metropolis Centres by promoting convenience.

### Strengthen Metropolis Brand



Expand Branded third-party PSCs to help create increased visibility and presence with limited investments and do a Direct to Patient approach.

### Productivity of existing young network



Increase number of referring doctors through a more efficient sales force leading to higher number of footfalls per centre.

### Wellness initiatives for consumers



Creating an easy and engaging way for consumers to directly interact with Metropolis and start making decisions about their own inner health.

## Build Industry Best practices

Introducing Standardized Machines and SOPs in a phased manner resulting in efficiency and quality enhancement

## Access to Metropolis Network


Providing acquired entities access to Metropolis Sales and Marketing Network to improve the Customer experience

## Brand Strength

Metropolis Brand allows the Acquired Entity to strengthen its position in the Local Market

## Test Menu Enhancement

Introducing Metropolis range of Test Menu to increase the capabilities of the Acquired Entity and thereby Customer experience



**Established Track Record of Successful Acquisition and Integration**



# Successful Track Record of Inorganic Strategy : 22 Acquisitions in 15 years

Few of the Acquired Companies	Year of Acquisition	Location	Revenue at the time of acquisition	Revenue for FY20
Sudharma Metropolis Health Services Private Limited	2003	Kerala	Rs. 1.8 Crores	Rs. 49.6 Crores
Golwilkar Metropolis Health Services (India) Private Limited	2006	Pune	Rs. 3.9 Crores	Rs. 41.3 Crores
Desai Metropolis Health Services Private Limited	2008	Surat	Rs. 3.4 Crores	Rs. 39.2 Crores
R.V. Metropolis Diagnostics & Healthcare Centre Private Limited	2008	Bangalore	Rs. 3.6 Crores	Rs. 43.5 Crores
Dr. Patel Metropolis Healthcare Private Limited	2012	Nasik	Rs. 1.8 Crores	Rs. 14.6 Crores
Sanjeevani Rajkot	2017	Rajkot	Rs. 12.0 Crores	Rs. 18.1 Crores

Metropolis has successfully improved the Performance of the Acquired Businesses as well as grow scale of operations, achieve economies of scale and increase operating efficiency thereby improving Market Position



# Plenty of Opportunities for Growth...



## Test Packages

Growing our offering of Test Packages to Increase Revenue Metrics. Customized packages to Institutional Customers and Personalized Packages to Individual Patients are key



## Scientific Upselling

Leverage our vast capabilities in Molecular Diagnostics, Oncology, Cytogenic where there is Less Competition and Higher Margins due to Advanced Technology, Skilled Manpower and Complex Processes Involved



## Public Private Partnership

Selectively Participate in PPP Tenders in India by leveraging our experience with the execution of the NACO Order. Large opportunities exist in African markets on PPP basis



## Preventive and Wellness Services

Targeting healthy individuals with sedentary lifestyles are prone to diseases such as cardiovascular and diabetes ailments. Precision medicine, focus on preventive care, walk-in/direct-to-customer services to drive growth



## Expansion

Aggressive Network Expansion to go closer to Patient

+

Seeding Cities emerging as New Focused Cities

67% of Existing Patient Touch Points added during FY17-20.

Maturity of this Young Network will fuel growth


Inorganic Strategy of Expanding Metropolis Reach to more locations in existing cities of presence and new cities

**STRENGTHEN METROPOLIS BRAND TO**

**'BE THE ONLY CHOICE OF PATIENTS'**



# Pan India Presence...




## Metropolis Service Network


Metropolis Service Network	FY19	FY20
Laboratories	119	125
Owned PSC's	255	260
Third Party PSC's	1,506	1,873
ARC's	575	598
Total	2,455	2,731

# ... with Aggressive Network Expansion Strategy

**Laboratory Network**



**Service Network**



## Network Strategy Highlights

### Young Individuals Patients Network

- ✓ 67% of the existing Individual patients touch points added during FY2017-20
- ✓ The average retail centre matures in five years. As the network matures, it is expected to contribute to short and mid term future growth

### Asset Light Network


- ✓ 90.5% of the centre network is asset light
- ✓ 10 of 13 labs added in FY19 via lab on lease model which is asset light with no capital requirement
- ✓ one of five labs added in FY20 via lab on lease model which is asset light with no capital requirement

### Fast Pace of Execution


- ✓ 6.4x patients network growth during FY2016-20
- ✓ 2,303 patients touch points added during FY2016-20

# Better than industry growth

Revenue (In Rs. Crs.)



Revenue growth for B2C (In Rs. Crs.)



## Bolstering Growth in Wellness Segment



Metropolis Wellness revenue contribution for Metropolis is 7.9% in FY20



This market is expected to grow at a CAGR of 20% over next 3 financial years (Frost & Sullivan)



Customers today are serious about wellness and choose to undergo preventive screening to safeguard their health and diagnose conditions before they turn in to complications




This segment is termed as wellness as opposed to the illness wherein the patient has to undergo tests when they are prescribed tests during sickness




Wellness & Preventive Diagnostics market is 7% to 9% in FY2018 (Frost & Sullivan)

# Robust Operating & Financial Performance


No. of Patient Visits (In Mn.)




Revenue Per Patient (In Rs.)



No. of Tests (In Mn.)



Revenue Per Test (In Rs.)



**Metropolis realization per test and sample is higher than industry owing to:-**

- ✓ ~37% of specialised test contributes to high revenue per test
- ✓ International business leads to higher realization per test
- ✓ Institutional customers contribute to higher realization per patient

Retail contribution in Focus Cities to Total Revenue




Chart shows B2C contribution over the years in focus cities; Mumbai, Chennai, Bangalore, Surat and Pune

Primary Strategy of the Company is to increase the Retail share in focus cities to **65%**


## B2C contribution in the last few years has seen an upward trend owing to:-

- ✓ Aggressive network expansion to go closer to the patient
- ✓ Integrated Brand building campaigns to establish Metropolis as a trusted brand in the mind of consumer and the doctor
- ✓ Building awareness amongst doctors for quality and service differentiators of Metropolis vs the unorganized sector
- ✓ Obsessively monitoring customer experience and generating an NPS (\*Net Promoters Score) of 91 across the group




# Financial Highlights


Revenue (In Rs. Crs.)




Reported EBITDA (In Rs. Crs.)




ROCE (%)




EBITDA (%)



Reported PAT (In Rs. Crs.)



ROE (%)



# Profit & Loss Statement

Profit & Loss (Rs. Crs.)	FY20	FY19	FY18	FY17	FY16
<b>Revenue from Operations</b>	<b>855.5</b>	<b>760.1</b>	<b>643.6</b>	<b>544.7</b>	<b>475.5</b>
Cost of Material Consumed	204.1	173.5	145.9	135.1	124.6
Laboratory testing charges	6.9	5.6	5.7	2.5	3.1
<b>Total Raw Material</b>	<b>211.0</b>	<b>179.1</b>	<b>151.6</b>	<b>137.6</b>	<b>127.7</b>
<b>Gross Profit</b>	<b>644.5</b>	<b>581.0</b>	<b>492.0</b>	<b>407.1</b>	<b>347.8</b>
<b>Gross Profit (%)</b>	<b>75.33%</b>	<b>76.44%</b>	<b>76.44%</b>	<b>74.74%</b>	<b>73.14%</b>
Employee Expenses	190.2	172.7	145.8	127.7	108.2
Other Expenses	222.4	202.8	173.7	124.8	109.8
<b>Reported EBITDA</b>	<b>231.9</b>	<b>205.4</b>	<b>172.5</b>	<b>154.6</b>	<b>129.8</b>
<b>Reported EBITDA (%)</b>	<b>27.11%</b>	<b>27.04%</b>	<b>26.80%</b>	<b>28.38%</b>	<b>27.30%</b>
Other Income	8.3	8.8	11.3	22.9	15.2
Depreciation	39.3	20.1	19.2	17.2	16.6
<b>EBIT</b>	<b>201.0</b>	<b>188.4</b>	<b>164.6</b>	<b>160.3</b>	<b>128.4</b>
<b>EBIT (%)</b>	<b>23.49%</b>	<b>24.79%</b>	<b>25.57%</b>	<b>29.43%</b>	<b>27.00%</b>
Finance Cost	7.2	0.5	1.2	0.4	0.8
Exceptional Items	24.5	6.3	-	-	-
Share of Profit/Loss from JV	-0.5	-1.4	-	-	-
<b>Profit Before Tax</b>	<b>168.7</b>	<b>186.5</b>	<b>163.4</b>	<b>159.9</b>	<b>127.6</b>
<b>Profit Before Tax (%)</b>	<b>19.72%</b>	<b>24.54%</b>	<b>25.39%</b>	<b>29.36%</b>	<b>26.83%</b>
Tax	41.2	62.9	51.8	52.7	45.6
<b>Profit After Tax</b>	<b>127.6</b>	<b>123.6</b>	<b>111.6</b>	<b>107.2</b>	<b>82</b>
<b>Profit After Tax (%)</b>	<b>14.91%</b>	<b>16.36%</b>	<b>17.34%</b>	<b>19.68%</b>	<b>17.25%</b>

# Balance Sheet

Assets (Rs. Crs.)	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
<b>Non-current assets</b>	<b>355.2</b>	<b>247.9</b>	<b>230.1</b>	<b>230.1</b>	<b>170.6</b>
Property, Plant and Equipment	121.2	116.7	112.3	105.2	105.6
Capital Work In-Progress	0.0	0.0	0.0	1.0	0.6
Goodwill	90.3	78.6	78.4	82.5	35.1
Other intangible assets	25.2	17.6	16.8	14.7	1.0
Intangible assets under development	3.0	5.8	0.0	0.0	0.0
ROU Assets	59.7	0.0	0.0	0.0	0.0
Equity accounted investees	0.0	0.5	0.0	6.0	5.4
<b>Financial Assets</b>					
(i) Investments	1.8	1.8	1.8	1.8	1.8
(ii) Loans	5.5	4.2	3.3	3.7	8.3
(iii) Other Financial Assets	12.4	10.2	8.3	2.2	0.0
Deferred Tax Assets (Net)	13.9	3.7	5.3	3.4	5.2
Other non-current assets	6.4	1.6	2.0	8.6	5.8
Non-current tax assets (net)	15.9	7.5	1.9	1.0	1.8
<b>Current assets</b>	<b>397.1</b>	<b>304.7</b>	<b>300.4</b>	<b>285.1</b>	<b>225.3</b>
Inventories	24.4	26.1	21.2	14.1	15.6
<b>Financial Assets</b>					
(i) Investments	12.6	31.0	100.4	134.1	94.2
(ii) Trade receivables	128.2	136.8	100.7	80.3	70.2
(iii) Cash and cash equivalents	107.2	51.4	43.5	25.5	26.8
(iv) Bank balances other than (iii)	103.3	28.9	16.7	15.0	6.8
(v) Loans	11.2	15.1	10.8	9.6	7.3
(vi) Other Financial Assets	2.2	8.4	1.4	0.5	0.5
Current tax assets (net)	0.0	0.0	0.0	0.1	0.3
Other Current Assets	8.0	7.0	5.7	5.9	3.6
<b>TOTAL - ASSETS</b>	<b>752.2</b>	<b>552.6</b>	<b>530.5</b>	<b>515.2</b>	<b>395.9</b>

Equity & Liabilities (Rs. Crs.)	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
<b>Equity</b>	<b>525.2</b>	<b>420.0</b>	<b>429.1</b>	<b>344.1</b>	<b>293.9</b>
Equity Share capital	10.1	10.0	9.5	9.5	9.5
Other equity	513.4	408.5	405.2	313.6	269.2
Non Controlling Interest	1.7	1.4	14.4	21.0	15.2
<b>LIABILITIES</b>					
<b>Non-current liabilities</b>	<b>57.6</b>	<b>8.2</b>	<b>10.5</b>	<b>19.3</b>	<b>11.1</b>
<b>Financial Liabilities</b>					
(i) Borrowings	0.0	0.0	0.2	0.4	0.5
(ii) Lease Liabilities	45.8	0.0	0.0	0.0	0.0
(iii) Other Non-Current Liabilities	4.7	2.1	2.4	8.7	0.3
Provisions	5.4	3.2	3.5	3.2	2.4
Deferred tax liabilities (Net)	1.7	2.9	4.4	7.0	7.9
<b>Current liabilities</b>	<b>169.5</b>	<b>124.5</b>	<b>90.9</b>	<b>151.8</b>	<b>90.9</b>
<b>Financial Liabilities</b>					
(i) Borrowings	0.0	17.6	0.4	0.4	0.4
(ii) Lease Liabilities	20.9	0.0	0.0	0.0	0.0
(iii) Trade Payables	85.0	53.4	35.4	35.9	32.8
(iv) Other Current Financial Liabilities	34.4	31.3	34.8	88.3	22.9
Other Current Liabilities	18.8	8.0	7.8	14.1	21.1
Provisions	6.6	4.9	4.4	3.7	3.7
Current tax liabilities (Net)	3.7	9.3	8.1	9.4	10.0
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>752.2</b>	<b>552.6</b>	<b>530.5</b>	<b>515.2</b>	<b>395.9</b>





**Dr. Sushil Kanubhai Shah**  
Chairman & Executive Director

Holds a bachelor's degree in Medicine and Surgery and a degree of Doctor of Medicine in Pathology and Bacteriology from University of Bombay. More than 3 decades of experience in Pathology business



**Ameera Sushil Shah**  
Managing Director

Holds a bachelor's degree in Business Administration from the University of Texas and also completed Owner-President Management Programme from Harvard Business School. More than 2 decades of experience in Pathology business



**Sanjay Bhatnagar**  
Independent Director

Holds a master's degree in Engineering from Stanford University and also master's degree in business administration from Harvard University



**Vivek Gambhir**  
Independent Director

Holds a bachelor's degree in Science & Arts from Lafayette College, Pennsylvania and a master's degree in Business Administration from Harvard University



**Milind Shripad Sarwate**  
Independent Director

Holds a bachelor's degree in Commerce from University of Bombay and is an associate of the ICAI, ICSI & ICWA



**Anita Ramachandran**  
Independent Director

MBA (Finance) from the Jamnalal Bajaj Institute, Mumbai and has won several academic honours



**Vijender Singh**  
Chief Executive Officer

Holds a bachelor's degree in Science from Kurukshetra University and completed an Executive Education Programme from the Indian School of Business, Hyderabad. More than 30 years of experience in business operations & Business Development



**Dr. Nilesh Shah**  
President and Chief of Science & Innovation

Holds a master's degree in Engineering from University of Mumbai and a Diploma in Medical Laboratory Technology from K.J Somaiya College of Science. More than 30 years of experience in science & innovation



**Ameera Sushil Shah**  
Managing Director



**Rakesh Agarwal**  
Chief Financial Officer

Holds a Master's in Business Administration with Finance Specializations from AIM Institute and CS from ICSI. He has over 20 years of progressive experience in Finance Domain including Business Finance, Financial Management & Operations Management.



**Ishita Medhekar**  
Chief Human Resource Officer

She has 20+ years of experience in varied industries such as telecom, Consultancy and Pharma with 15 years of experience in strategy and system designing and operations. In her recent assignments she has been associated with other organizations like Bharti Airtel, Avaya Global Connect, AF Ferguson & Co.



# Recent Awards and Accolades



Period	Particulars
November 2020	Our MD, <b>Ms. Ameera Shah</b> has been listed as the <b>Most Powerful Women</b> in India for the 4th consecutive year by Fortune India
October 2020	Metropolis Healthcare Ltd won the 2020 Indian <b>Diagnostic Services Industry Company of the Year Award</b> organised by Frost & Sullivan
September 2020	Our MD, <b>Ms. Ameera Shah</b> has been listed in <b>Asia's Power Businesswomen 2020</b> by Forbes Asia
August 2020	<b>Metropolis Healthcare Limited</b> won the award for <b>Health Impact Awareness Campaign</b> at the 4th CSR Impact Awards for TooShyToAsk
May 2020	<b>Metropolis Healthcare Limited</b> won the <b>Excellence in Corporate Social Responsibility</b> Award at the 8th India CSR Award for TooShyToAsk
February 2020	Our MD, <b>Ms. Ameera Shah</b> won the <b>Leader of the Year: NextGen</b> award at the CNBC-AWAAZ CEO Award organized by CNBC Awaaz held at Raipur
February 2020	Metropolis won the <b>Most Admired Healthcare Company of the Year</b> and our CEO, <b>Mr. Vijender Singh</b> won the <b>"Best Business Leader of the Year"</b> award at Business Leader of the Year Awards, 2020
February 2020	Lister Metropolis won the <b>Best Medical Diagnostic Company in Quality Excellence</b> award at the TANCARE 2020 organized by FICCI in association with the New Indian Express.
December 2019	Our Chairman, <b>Dr. Sushil Shah</b> , won the <b>'Lifetime Achievement Award'</b> at the South Asia Pacific Healthcare Summit & Business Awards, 2019 for his immense contribution to the diagnostic industry.
December 2019	Our MD, <b>Ms. Ameera Shah</b> won the <b>'Best Woman Entrepreneur of the Year'</b> in Healthcare Sector award at the ASSOCHAM Women Leadership & Empowerment Summit & Awards for her outstanding leadership and achievements in the diagnostic industry.



For further information, please contact:

**Company :**

**Investor Relations Advisors :**



Metropolis Healthcare Ltd.  
CIN – L73100MH2000PLC192798  
Mr. Rakesh Agarwal - CFO  
Email Id – [rakesh.agarwal@metropolisindia.com](mailto:rakesh.agarwal@metropolisindia.com)

[www.metropolisindia.com](http://www.metropolisindia.com)

**SGA** Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.  
CIN - U74140MH2010PTC204285  
Mr. Shogun Jain / Mr. Sagar Shroff  
[shogun.jain@sgapl.net](mailto:shogun.jain@sgapl.net) / [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net)  
+91 77383 77756 / +91 98205 19303

[www.sgapl.net](http://www.sgapl.net)